Vismodegib
- Generic Name
- Vismodegib
- Brand Names
- Erivedge
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14Cl2N2O3S
- CAS Number
- 879085-55-9
- Unique Ingredient Identifier
- 25X868M3DS
- Background
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling p...
- Indication
用于不能手术或放疗的局部晚期皮肤基底细胞癌患者和肿瘤已转移的患者。
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Metastatic Basal cell carcinoma
- Associated Therapies
- -
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 118
- Registration Number
- NCT01064622
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 124
- Registration Number
- NCT00982592
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸New York Cancer Consortium, Bronx;, New York, United States
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
- First Posted Date
- 2009-09-21
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00980343
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of California at Los Angeles, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
- Conditions
- Interventions
- First Posted Date
- 2009-08-14
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT00959647
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
- Conditions
- Interventions
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00939484
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸UCSF Medical Center-Mount Zion, San Francisco, California, United States
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 168
- Registration Number
- NCT00887159
- Locations
- 🇺🇸
Boca Raton Regional Hospital, Boca Raton, Florida, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸Longmont United Hospital, Longmont, Colorado, United States
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00878163
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Orlando Health Cancer Institute, Orlando, Florida, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
- Conditions
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT00822458
- Locations
- 🇺🇸
UCSF-Mount Zion, San Francisco, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.